Difference between revisions of "Esmolol"
Sydney Caley (talk | contribs) (Added information about esmolol) |
(Added onset of action and metabolism details, specifically RBC esterase metabolism.) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
| contraindications = | | contraindications = | ||
| routes = Intravenous | | routes = Intravenous | ||
| dosage = | | dosage = | ||
| dosage_calculation = esmolol | | dosage_calculation = esmolol | ||
| mechanism = Beta-1 antagonism | | mechanism = Beta-1 antagonism | ||
| Line 50: | Line 46: | ||
=== Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> === | === Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> === | ||
==== Onset of action ==== | |||
Beta-blockade with esmolol can be observed within 2-10 minutes of administration. Onset is typically quicker when administered as a bolus or with a loading dose prior to infusion.<ref name=":1" /> | |||
==== Metabolism ==== | |||
Esmolol is metabolized by red blood cell esterases to inactive metabolites, which are renally excreted. <ref name=":1" /> | |||
== Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. --> == | == Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. --> == | ||
Latest revision as of 09:07, 31 May 2023
| Trade names |
Brevibloc |
|---|---|
 | |
| Clinical data | |
| Drug class |
Beta blocker |
| Routes of administration |
Intravenous |
| Dosage | |
| Pharmacodynamics | |
| Mechanism of action |
Beta-1 antagonism |
| Adverse effects |
Bradycardia, Hypotension |
| Pharmacokinetics | |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Esmolol is an ultrashort-acting selective β1-antagonist. It primarily decreases heart rate with less of an effect on blood pressure. [1]
Uses
Treat/prevent perioperative tachycardia and hypertension .
Opioid sparing anesthesia.[1]
Contraindications
Absolute contraindications
Precautions
While it is cardioselective at lower doses, use higher doses cautiously in patients with bronchospastic disease. [2]
Extreme caution should be used in patients with bradycardia, hypotension, greater than first degree heart block, cardiogenic shock or heart failure with reduced ejection fraction.[1] Avoid in patients who recently received a calcium channel blocker. [2]
Pharmacology
Pharmacodynamics
Mechanism of action
At normal doses it is a selective β1-antagonist, at higher doses it also inhibits β2 receptors in both bronchial and vascular smooth muscle. [1]
Adverse effects
Pharmacokinetics
Onset of action
Beta-blockade with esmolol can be observed within 2-10 minutes of administration. Onset is typically quicker when administered as a bolus or with a loading dose prior to infusion.[2]
Metabolism
Esmolol is metabolized by red blood cell esterases to inactive metabolites, which are renally excreted. [2]
Chemistry and formulation
History
References
- ↑ 1.0 1.1 1.2 1.3 Morgan & Mikhail's clinical anesthesiology. John F., IV Butterworth, David C. Mackey, John D. Wasnick (Seventh edition ed.). New York. 2022. ISBN 9781260473797. OCLC 1309921315.
|edition=has extra text (help)CS1 maint: others (link) - ↑ 2.0 2.1 2.2 2.3 "UpToDate - Esmolol: Drug information". www.uptodate.com. Retrieved 2022-12-21.